Five agents are currently approved by the Therapeutic Goods Administration (TGA) for obesity management: orlistat, phentermine, naltrexone–bupropion, and the glucagon‐like peptide 1 (GLP‐1) receptor agonists liraglutide and semaglutide. This evidence concerns the gene GLP1R and obesity disorder.